In vivo electrochemical studies of dopamine overflow and clearance in the striatum of normal and MPTP-treated rhesus monkeys

Journal of Neurochemistry

Volumn 66, Issue 2, 1996, Pages 579-588

  Gerhardt, Greg A ^a   Cass, Wayne A ^b   Hudson, John ^a   Henson, Mike ^a   Zhang, Zhiming ^b   Ovadia, Aliza ^b   Hoffer, Barry J ^a   Gash, Don M ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Dopamine; In vivo electrochemistry; Monkeys; Parkinson's disease; Striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

ADOLESCENT; AGED; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; DOPAMINE BLOOD LEVEL; DOPAMINE RELEASE; ELECTROCHEMICAL DETECTION; ELECTROCHEMISTRY; FEMALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; RHESUS MONKEY; STEREOTAXIC SURGERY;

ANIMALIA; MACACA MULATTA;

EID: 0030043991     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1996.66020579.x     Document Type: Article

References (52)

1. Bankiewicz K. S., Oldfield E. H., Chiueh C. C., Doppman J. L., Jacobowitz D. M., and Kopin I. J. (1986) Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 39, 7-16.
2. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., and Seitelberger F. (1973) Brain dopamine and the syndromes of Parkinson and Huntington. J. Neurol. Sci. 20, 415-455.
3. Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobowitz D. M., and Kopin I. J. (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80, 4546-4550.
4. Carman L. S., Gage F H., and Shults C. W. (1991) Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior. Brain Res. 553, 275-283.
5. Casas M., Ferre S., Cobos A., Cadafalch J., Grau J. M., and Jane F. (1988) Comparison between apomorphine and amphetamine-induced rotational behaviour in rats with a unilateral nigrostriatal pathway lesion. Neuropharmacology 27, 657-659.
6. Cass W A., Zahniser N. R., Flach K. A., and Gerhardt G. A. (1993) Clearance of exogenous dopamine in rat dorsal striatum and nucleus accumbens: role of metabolism and effects of locally applied uptake inhibitors. J. Neurochem. 61, 2269-2278.
7. Cass W. A., Gerhardt G. A., Zhang Z., Ovadia A., and Gash D. M. (1995) Increased dopamine clearance in the non-lesioned striatum of rhesus monkeys with unilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) striatal lesions. Neurosci. Lett. 185, 52-55.
8. Cheney-Thamm J., Alianello E. A., Freed C. R., and Reite M. (1987) In vivo electrochemical recording of acetaminophen in nonhuman primate brain. Life Sci. 40, 375-379.
9. Duvoisin R. C. (1991) Parkinson's Disease: A Guide for Patient and Family, pp. 1-180. Raven Press, New York.
10. Fiandaca M. S., Kordower J. H., Hansen J. T., Jlao S.-S., and Gash D. M. (1988) Adrenal medullary autografts into the basal ganglia of cebus monkeys: injury-induced regeneration. Exp. Neurol. 102, 76-91.
11. Friedemann M. and Gerhardt G. A. (1992) Regional effects of aging on dopaminergic function in the Fischer-344 rat. Neurobiol. Aging 13, 325-332.
12. Garris P. A. and Wightman R. M. (1994) Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J. Neurosci. 14, 442-450.
13. Garris P. A., Collins L. B., Jones S. R., and Wightman R. M. (1993) Evoked extracellular dopamine in vivo in the medial prefrontal cortex. J. Neurochem. 61, 637-647.
14. Gerhardt G. A., Oke A. F., Nagy G., Moghaddam B., and Adams R. N. (1984) Nafion-coated electrodes with high selectivity for CNS electrochemistry. Brain Res. 290, 390-395.
15. Gerhardt G., Rose G., Strömberg I., Conboy G., Olson L., Jonsson G., and Hoffer B. (1985) Dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse: an in vivo electrochemical study. J. Pharmacol. Exp. Ther. 235, 259-265.
16. Gerhardt G. A., Rose G. M., and Hoffer B. J. (1986) Release of monoamines from striatum of rat and mouse evoked by local application of potassium: evaluation of a new in vivo electrochemical technique. J. Neurochem. 46, 842-850.
17. Gerhardt G. A., Friedemann M., Brodie M. S., Vickroy T. W , Gratton A. P., Hoffer B. J , and Rose G. M. (1989) The effects of cholecystokinin (CCK-8) on dopamine-containing nerve terminals in the caudate nucleus and nucleus accumbens of the anesthetized rat: an in vivo electrochemical study. Brain Res. 499, 157-163.
18. Gratton A., Hoffer B. J., and Gerhardt G. A. (1989) In vivo electrochemical studies of monoamine release in the medial prefrontal cortex of the rat. Neuroscience 29, 57-64.
19. Hall M. A., Hoffer B. J., and Gerhardt G. A. (1989) Rapid and sensitive determination of catecholamines in small tissue samples by high pressure liquid chromatography coupled with dual-electrode coulometric electrochemical detection. LC/GC 7, 258-265.
20. Heikkila R. E., Nicklas W. J., and Duvoisin R. C. (1984) Dopamineric neurotoxicity of methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science 224, 1451-1453.
21. Hoehn M. M. and Yahr M. D. (1967) Parkinsonism: onset progression and mortality. Neurology 17, 427-442.
22. Hornykiewicz O. (1971) Neurochemical pathology and pharmacology of brain dopamine and acetylcholine: rational basis for the current drug treatment of parkinsonism. Contemporary Neurology Series 8, 33-65.
23. Hornykiewicz O. and Kish S. J. (1987) Biochemical pathology of Parkinson's disease. Adv. Neurol. 45, 19-34.
24. Hudson J. L., van Horne C. G., Strömberg I., Brock S., Clayton J., Masserano J., Hoffer B. J., and Gerhardt G. A. (1993) Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res. 626, 167-174.
25. Jellinger K. (1986) Overview of morphological changes in Parkinson's disease. Adv. Neurol. 45, 1-18.
26. Kastner A., Hirsch E. C., Javoy-Agid F., and Agid Y. (1993a) Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease. Brain Res. 606, 341-345.
27. Kastner A., Hirsch E. C., Herrero M. T., Javoy-Agid F., and Agid Y. (1993b) Immunocytochemical quantification of tyrosine hydroxylase at a cellular level in the mesencephalon of control subjects and patients with Parkinson's and Alzheimer's disease. J. Neurochem. 61, 1024-1034.
28. Kastner A., Herrero M. T., Hirsch E. C., Guillen J., Luquin M. R., Javoy-Agid F., Obeso A., and Agid Y. (1994) Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy. Ann. Neurol. 36, 206-214.
29. Kawagoe K. T., Zimmerman J. B., and Wightman R. M. (1993) Principles of voltammetry and microelectrode surface states. J. Neurosci. Methods 48, 225-240.
30. Kurlan R., Kim M. H., and Gash D. M. (1991) Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Mov. Disord. 6, 111-118.
31. Langston J. W., Ballard P., Tetrud J. W., and Irwin I. (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980.
32. Leenders K. L., Aquilonius S.-M., Bergström K., Bjurling P., Crossman A. R., Eckernas S.-Å., Gee A. G , Hartvig P., Lundqvist H., Längström B., Rimland A., and Tedroff J. (1988) Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Res. 445, 61-67.
33. Leenders K. L., Salmon E. P., Tyrrell P., Perani D., Brooks D. J., Sager H., Jones T., Marsden C. D., and Frackowiak R. S. J. (1990) The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch. Neurol. 47, 1290-1298.
34. Lindsay W. S., Herndon J. G. Jr., Blakely R. D., Justice J. B. Jr., and Neill D. B. (1981) Voltammetric recording from neostriatum of behaving rhesus monkey. Brain Res. 220, 391-396.
35. Lynd-Balta E. and Haber S. N. (1994a) The organization of midbrain projections to the ventral striatum in the primate. Neuroscience 59, 609-623.
36. Lynd-Balta E. and Haber S. N. (1994b) The organization of midbrain projections to the striatum in the primate: sensorimotor-related striatum versus ventral striatum. Neuroscience 59, 625-640.
37. Marshall J. F. and Ungerstedt U. (1977) Supersensitivity to apomorphine following destruction of the ascending dopamine neurons: quantification using the rotational model. Eur. J. Pharmacol. 41, 361-367.
38. Moghaddam B., Berridge C. W., Goldman-Rakic P. S., Bunney B. S., and Roth R. H. (1993) In vivo assessment of basal and drug-induced dopamine release in cortical and subcortical regions of the anesthetized primate. Synapse 13, 215-222.
39. Nicholson C. (1995) Interaction between diffusion and Michaelis-Menten uptake of dopamine after iontophoresis in striatum. Biophys. J. 68, 1699-1715.
40. Rice M. E., Gerhardt G. A., Hierl P. M., Nagy G., and Adams R. N. (1985) Diffusion coefficients of neurotransmitters and their metabolites in brain extracellular fluid space. Neuroscience 15, 891-902.
41. + (1-methyl-4-phenylpyridinium) in three species: microdialysis of dopamine and metabolites in mouse, rat and monkey striatum. Neurosci. Lett. 106, 275-281.
42. Saunders R. C., Kolachana B. S., and Weinberger D. R. (1994) Local pharmacological manipulation of extracellular dopamine levels in the dorsolateral prefrontal cortex and caudate nucleus in the rhesus monkey: an in vivo microdialysis study. Exp. Brain Res. 98, 44-52.
43. Schneider J. S., Rothblatt D. S., and DiStefano L. (1994) Volume transmission of dopamine over large distances may contribute to recovery from experimental parkinsonism. Brain Res. 643, 86-91.
44. Skirboll S., Wang J., Mefford I., Hsiao J., and Bankiewicz K. S. (1990) In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis. Exp. Neurol. 110, 187-193.
45. Smith R. D., Zhang Z., Kurlan R., McDermott M., and Gash D. M. (1993) Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neuroscience 52, 7-16.
46. Uhl G. R., Walther D., Mash D., Faucheaux B., and Javoy-Agid F. (1994) Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann. Neurol. 35, 494-498.
47. Ungerstedt U. (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5, 107-110.
48. Ungerstedt U. and Herrera-Marschitz M. (1981) Behavioral pharmacology of dopamine receptor mechanisms, in Chemical Neurotransmission: 75 Years (Stjarne L., Hedqvist P., Lagercrantz H., and Wennmalm A., eds), pp. 481-494. Academic Press, London.
49. van Horne C., Hoffer B. J., Strömberg I., and Gerhardt G. A. (1992) Clearance and diffusion of locally applied dopamine in normal and 6-hydroxydopamine-lesioned rat striatum. J. Pharmacol. Exp. Ther. 263, 1285-1292.
50. Wang J., Skirboll S., Aigner T. G., Saunders R. C., Hsiao J., and Bankiewicz K. S. (1990) Methodology of microdialysis of neostriatum in hemiparkinsonian nonhuman primates. Exp. Neurol 110, 181-186.
51. Zigmond M. J., Abercrombie E. D., Berger T. W., Grace A. A., and Stricker E. M. (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 12, 290-296.
52. Zigmond M. J., Hastings T. G., and Abercrombie E. D. (1992) Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease. Ann. NY Acad Sci. 648, 71-86.